Literature DB >> 19051299

The t-PA-encapsulated PLGA nanoparticles shelled with CS or CS-GRGD alter both permeation through and dissolving patterns of blood clots compared with t-PA solution: an in vitro thrombolysis study.

Shoei-Shen Wang1, Nai-Kuan Chou, Tze-Wen Chung.   

Abstract

Accelerated thrombolysis by pressure-driven permeation has been demonstrated in in vitro and in vivo animal models by using plasminogen activators (PAs) encapsulated liposomes or PEG microparticles. Recent reports have also described acceleration of thrombolysis using tissue type PA (t-PA) encapsulated in PLGA nanoparticles (NPs) coated with chitosan (CS) or CS-GRGD by interactions between the NPs and blood clots. However, the permeation through and dissolving patterns in thrombolysis with the aforementioned microparticles or NPs, which may be clinically relevant to the recovery status of the posttreatments, have not been reported. Therefore, this work studied such phenomena in thrombolysis with t-PA encapsulated in NPs. The t-PA solution and the NPs exhibited distinctly different permeation patterns of dissolved clots. Plasma permeates through clots showed a stream flow or burst flow phenomena when lyzed with NPs shelled with CS or CS-GRGD, respectively, whereas a diffusion pattern was observed in those lyzed with t-PA solution. At the outlet position of clots, the clots dissolved with PLGA/CS and PLGA/CS-GRGD NPs revealed extremely rough surfaces to a depth of 100 mum, indicating that a cross-permeation direction of clot lysis occurred, while those dissolved with t-PA solution showed slightly rough surfaces to a depth of 12 mum. Permeation through and clot dissolution patterns of thrombolysis with t-PA encapsulated in NPs shelled with CS or CS-GRGD distinctly differed from those dissolved with t-PA solutions in this in vitro thrombolysis model, These findings may be relevant to posttreatment of patients with conventional PA thrombolysis. Copyright 2008 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19051299     DOI: 10.1002/jbm.a.32234

Source DB:  PubMed          Journal:  J Biomed Mater Res A        ISSN: 1549-3296            Impact factor:   4.396


  13 in total

Review 1.  Translational initiatives in thrombolytic therapy.

Authors:  Melvin E Klegerman
Journal:  Front Med       Date:  2017-03-02       Impact factor: 4.592

2.  Tissue plasminogen activator-based nanothrombolysis for ischemic stroke.

Authors:  Shan Liu; Xiaozhou Feng; Rong Jin; Guohong Li
Journal:  Expert Opin Drug Deliv       Date:  2017-09-28       Impact factor: 6.648

3.  In vivo thrombolysis with targeted microbubbles loading tissue plasminogen activator in a rabbit femoral artery thrombus model.

Authors:  Xing Hua; Lina Zhou; Ping Liu; Yun He; Kaibin Tan; Qinghai Chen; Yuejuan Gao; Yunhua Gao
Journal:  J Thromb Thrombolysis       Date:  2014-07       Impact factor: 2.300

Review 4.  Advanced drug delivery systems for antithrombotic agents.

Authors:  Colin F Greineder; Melissa D Howard; Ronald Carnemolla; Douglas B Cines; Vladimir R Muzykantov
Journal:  Blood       Date:  2013-06-24       Impact factor: 22.113

5.  An In Vitro Thrombolysis Study Using a Mixture of Fast-Acting and Slower Release Microspheres.

Authors:  Hoai X Nguyen; Edgar A O'Rear
Journal:  Pharm Res       Date:  2016-03-10       Impact factor: 4.200

6.  Fibrinolytic PLGA nanoparticles for slow clot lysis within abdominal aortic aneurysms attenuate proteolytic loss of vascular elastic matrix.

Authors:  Balakrishnan Sivaraman; Andrew Sylvester; Anand Ramamurthi
Journal:  Mater Sci Eng C Mater Biol Appl       Date:  2015-09-16       Impact factor: 7.328

7.  Elongated Plant Virus-Based Nanoparticles for Enhanced Delivery of Thrombolytic Therapies.

Authors:  Andrzej S Pitek; Yunmei Wang; Sahil Gulati; Huiyun Gao; Phoebe L Stewart; Daniel I Simon; Nicole F Steinmetz
Journal:  Mol Pharm       Date:  2017-09-26       Impact factor: 4.939

8.  Urokinase-coated chitosan nanoparticles for thrombolytic therapy: preparation and pharmacodynamics in vivo.

Authors:  Hai-jiang Jin; Hao Zhang; Min-li Sun; Bai-gen Zhang; Ji-wei Zhang
Journal:  J Thromb Thrombolysis       Date:  2013-11       Impact factor: 2.300

Review 9.  Thrombolytic Agents: Nanocarriers in Controlled Release.

Authors:  Soodabeh Hassanpour; Han-Jun Kim; Arezoo Saadati; Peyton Tebon; Chengbin Xue; Floor W van den Dolder; Jai Thakor; Behzad Baradaran; Jafar Mosafer; Amir Baghbanzadeh; Natan Roberto de Barros; Mahmoud Hashemzaei; Kang Ju Lee; Junmin Lee; Shiming Zhang; Wujin Sun; Hyun-Jong Cho; Samad Ahadian; Nureddin Ashammakhi; Mehmet R Dokmeci; Ahad Mokhtarzadeh; Ali Khademhosseini
Journal:  Small       Date:  2020-08-12       Impact factor: 13.281

Review 10.  New Approaches in Nanomedicine for Ischemic Stroke.

Authors:  Clara Correa-Paz; Andrés da Silva-Candal; Ester Polo; Jérôme Parcq; Denis Vivien; Dusica Maysinger; Beatriz Pelaz; Francisco Campos
Journal:  Pharmaceutics       Date:  2021-05-20       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.